MapLight News
MapLight is continuously hitting new milestones in our mission to develop therapeutics with the potential to improve the lives of those with difficult-to-treat brain disorders. Check back for additional news related to our programs and organization.
MapLight Therapeutics Announces Results from Phase 1 Trial
MapLight Therapeutics today announced results from its Phase 1 trial evaluating the safety, tolerability and pharmacokinetics of ML-007/PAC in healthy adult and elderly volunteers.
MapLight Therapeutics Appoints Maria Walker to Board of Directors
MapLight Therapeutics Appoints Maria Walker to Board of Directors Walker brings 30+ years of investment, operational, and advisory experience SAN FRANCISCO AND BOSTON, APRIL 3,
MapLight Therapeutics Announces Initiation of Phase 1 Clinical Trial for ML-007/PAC, Under Development for Schizophrenia and Alzheimer’s Disease Psychosis
MapLight Therapeutics Announces Initiation of Phase 1 Clinical Trial for ML-007/PAC, Under Development for Schizophrenia and Alzheimer’s Disease Psychosis Study to evaluate safety and tolerability
MapLight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer
MapLight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer Mr. Setia brings significant advisory and execution experience across capital
MapLight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M₁/M₄ Muscarinic Agonist in Development for Schizophrenia and Alzheimer’s Disease Psychosis
MapLight Therapeutics Announces Completion of Phase 1 Clinical Trial for Novel M1/M4 Muscarinic Agonist in Development for Schizophrenia and Alzheimer’s Disease Psychosis Extended-release ML-007 was
MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of CNS Therapeutics
MapLight Therapeutics Closes $225 Million Series C Funding Round to Advance Pipeline of Central Nervous System Therapeutics Funding will support development of multiple clinical candidates
Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007
MapLight Therapeutics Announces Successful Completion of Second Phase 1 Clinical Trial of the Novel Muscarinic Receptor Agonist ML-007 Study assessed safety, tolerability, and pharmacokinetics (PK)
MapLight Therapeutics Appoints Tim Garnett, M.D. to Board of Directors
MapLight Therapeutics Appoints Tim Garnett, M.D. to Board of Directors Industry Leader Appointed to MapLight’s Board of Directors SAN FRANCISCO, July 24, 2023 –
MapLight Therapeutics Appoints Kris Hanson as General Counsel
MapLight Therapeutics Appoints Kris Hanson as General Counsel Hanson Brings 25 Years of Experience Advising Public and Private Companies to MapLight as the New Legal
MapLight Therapeutics Appoints Dr. Matthew State And Dr. Ivan Soltesz to Scientific Advisory Board
MapLight Therapeutics Appoints Dr. Matthew State and Dr. Ivan Soltesz to Scientific Advisory Board MapLight’s drug discovery expertise is further strengthened by the addition of
MapLight Therapeutics Appoints Hongkui Zeng, Ph.D. to Scientific Advisory Board
Dr. Zeng Brings Deep Expertise in Single-Cell Transcriptomics and Brian Circuit Connectivity to MapLight’s Scientific Advisory Board
MapLight Therapeutics Announces Completion Of Phase 1 Clinical Trial For ML-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias
18.08.2022 MapLight Therapeutics Announces Completion Of Phase 1 Clinical Trial For ML-007, A Novel Therapy For The Treatment Of Schizophrenia And Dyskinesias First in human
MapLight Therapeutics appoints Erin Pennock Foff, M.D., Ph.D., as Chief Medical Officer
Dr. Foff Joins MapLight to Help Further Advance the Company’s Portfolio of Novel Therapeutics for Patients with Disorders of the Central Nervous System (CNS).
